Navigation Links
Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
Date:4/23/2008

ndications, combinations and formulations."

Final results from patients in the international, open-label, multi-center Phase 2 trial were presented. An analysis of 62 deaths in 77 patients indicated a median overall survival of 27 weeks following picoplatin treatment administered once every 3 weeks. The most common side effects found in this present study were hematologic, including thrombocytopenia, anemia and neutropenia. No grade 3 or 4 neurotoxicity or nephrotoxicity and no treatment- related deaths occurred in this study. In addition, quality of life was preserved in the group of patients receiving picoplatin assessed every 3 weeks with Lung Cancer Symptom Scale (LCSS).

About Picoplatin

Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin has been evaluated in more than 750 patients and has anti-tumor activity in multiple indications with less severe kidney and nerve toxicity than is commonly observed with other platinum chemotherapy drugs.

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small cell lung cancer. This registrational trial currently is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration and is evaluating overall survival as the primary endpoint. The Company also is evaluating intravenous picoplatin in two ongoing Phase 2 clinical trials for the treatment of hormone-refractory prostate cancer and metastatic colorectal cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...gnostic Value of Circulating Tumor Cells, RARITAN...prospective,clinical trial found the number of cir...of progression-free and overall survival among met... report published in the July 1,issue of the Journ... the US, the Netherlands, and the United,Kingdom, ...
(Date:7/24/2008)... 24 /PRNewswire-USNewswire/ -- Headlines claiming ...hole story. The small scale,preliminary study tha...production, is based on recollected intake of soyf.... "This study is confounded by many,issues, thus I...al of,caution," warned Dr. Tammy Hedlund, a resear...
(Date:7/23/2008)...st Approved Systemic Therapy to Treat the Disease ...RNewswire-FirstCall/ --,Bayer HealthCare Pharmaceu...X) today announced that The New England Journal of...onstrating that Nexavar(R) (sorafenib),tablets dec... patients with,unresectable hepatocellular carcino...
(Date:7/23/2008)... Some Areas of the Body Have Greater Concentration... /PRNewswire-USNewswire/ -- Fat removed,from the l...as found to be,an excellent source of stem cells, ...eas of the body, reports a Brazilian-based study i...the official medical journal of the,American Socie...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Soyfoods Do Not Impact Sperm Count 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Data Show Common Allergy Tests Are Not Interchangeable 18816 1Data Show Common Allergy Tests Are Not Interchangeable 18816 2Data Show Common Allergy Tests Are Not Interchangeable 18816 3Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Angiotech to participate in Bank of America Health Care Conference 5229 1Federal polar bear research critically flawed says study in INFORMS journal 3237 1Federal polar bear research critically flawed says study in INFORMS journal 3237 2
...RE)--Jun 11, 2007 - Repros,Therapeutics Inc. (Nasd...ts six month study of Proellex in the treatment of...nrolled 39,premenopausal women and has completed s... levels of Proellex(TM) as well as a,positive cont...H,agonist also known as Lupron(R) or leuprolide ac...
...Jun 11, 2007 - Neurogen,Corporation (Nasdaq: NRGN)...linical studies for NG2-73, the Company,s lead com...d today at the SLEEP,2007 Annual Meeting of the As...nneapolis, Minnesota. Two Phase 2b clinical studie...rently being,conducted by the Company. Data presen...
Other Medicine Technology:Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 2Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 3Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 4Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 5Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care 6Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 2Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 3Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting 4
(Date:7/25/2008)..., N.Y., July 25 /PRNewswire-USNewswire/ -- Anthony...ality Officer and Vice President,of Strategic Plan...und, a,national foundation committed to improving ...the foundation,s Program on Health Care Quality,Im...scom.com/cgi-bin/prnh/20080725/DC28791LOGO ), Bo...
(Date:7/25/2008)...leaning products reduces lung function, increases ..., July 25 (HealthDay News) -- A clean, fresh-smell...nding on what type of cleaning and air freshening ...at exposure to cleaning products or air fresheners...(VOC) called 1,4 dicholorobenzene (1,4 DCB), can r...
(Date:7/25/2008)... Though the number of jobs created in the...anies reported a different kind of slowdown: they ...ths. , Seattle, WA (PRWEB...ed in the medical field slowed in June overall, ph...f slowdown that will be music to the ears of sales...
(Date:7/25/2008)... Corporation Executive, Robert J. Reilly, Joins Ae...thon Inc.,( http://www.aethon.com ), the leading d...ain logistics, today announced that Robert J. Reil... -- Chief Financial Officer., Reilly, who was mos...cKesson Corporation,s Specialty Pharmacy Division,...
Breaking Medicine News(10 mins):Health News:IPRO Welcomes Back Anthony Shih as Chief Quality Officer, Strategic Planning Lead 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Aethon, Inc. Names New Chief Financial Officer 2
...ion feels that Asia is facing an increased threat ...ur in. Dr. Shigeru Omi, Regional Director, WHO Wes... planning and working to combat bird flu spread bu...d should be done to prevent bird flu spread. It is...
...e that of viral flu are spreading across Delhi wit...Delhi recorded a minimum of 0.2 degrees Celsius (7...eek later the temperature reached 11.6 degrees //(... 2006. Doctors have called upon people to be caref...
...re exploring the possibility for using Kaiso prote...ping this new approach to treat intestinal cancer ...ciences, //under Anna Prokhorchuk's guidance joint... the international CRDF foundation and the Federal...
...Weizmann Institute of Science throws light on cell... old age. These findings appear in the February is...artz of the Neurobiology Department at Weizmann le...t implication in delaying the onset of cognitive d...
Other Medicine News:Health News:Methyl-DNA binding Proteins To Fight Cancer 2Health News:Weizmann Institute of Science says Immune Cells Could Help Maintain Brain Function 2
...Ovulation Predicting Test is a qualitative immunoa...e (hLH) in human urine to predict the occurrence o...on of human luteinizing hormone (hLH). Usually, ar...rief, significant rapid increase called the "LH su...
The Shandon Cryotome SME Cryostat model is a sophisticated, top of the line cryostat that combines automated electronic advance and hands-free sectioning with fully independent specimen temperature c
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning.
The Shandon Varistain Gemini is designed for high throughput, precision, safety, durability and ultimate flexibility in histology and cytology staining applications. It features load-on-demand multip
Medicine Products: